Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients (vol 5, pg 312, 2017)

被引：3
|
作者：
de Velasco, G.
Je, Y.
Bosse, D.
Awad, M. M.
Ott, P. A.
Moreira, R. B.
Schutz, F.
Bellmunt, J.
Sonpavde, G. P.
Hodi, F. S.
Choueiri, T. K.
机构：
来源：
CANCER IMMUNOLOGY RESEARCH | 2018年 / 6卷 / 04期
关键词：
D O I：
10.1158/2326-6066.CIR-18-0078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：498 / 499
页数：2
相关论文
共 50 条
  • [31] Immune-related adverse events (irAEs) with single-agent PD-1 vs PD-L1 inhibitors: A meta-analysis of 8,730 patients from clinical trials
    Sonpavde, G. P.
    Grivas, P.
    Lin, Y.
    Hennessy, D.
    Hunt, J. D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis
    Huo, Gengwei
    Liu, Wenjie
    Zhang, Sipei
    Chen, Peng
    IMMUNOTHERAPY, 2023, 15 (03) : 189 - 207
  • [33] Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
    Tunger, Antje
    Kiessler, Maximilian
    Wehner, Rebekka
    Temme, Achim
    Meier, Friedegund
    Bachmann, Michael
    Schmitz, Marc
    BIOMEDICINES, 2018, 6 (01)
  • [34] The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis
    Zhao, Pengfei
    Zhao, Ting
    Yu, Lihong
    Ma, Wenming
    Liu, Wenyu
    Zhang, Chenning
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [35] Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer A meta-analysis
    Zhang, Pei-Pei
    Wang, Juan
    Ding, Da-Zhi
    Zhang, Li
    Cheng, Chun
    Chen, Da-Ke
    MEDICINE, 2021, 100 (35) : E27121
  • [36] Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
    S A Quezada
    K S Peggs
    British Journal of Cancer, 2013, 108 : 1560 - 1565
  • [37] PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
    Song, Qingya
    Yu, Zongliang
    Lu, Wenping
    Zhuo, Zhili
    Chang, Lei
    Mei, Heting
    Cui, Yongjia
    Zhang, Dongni
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [38] Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
    Quezada, S. A.
    Peggs, K. S.
    BRITISH JOURNAL OF CANCER, 2013, 108 (08) : 1560 - 1565
  • [39] Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist
    Chadha, Simran
    Para, Andrew J.
    Choi, Jennifer
    CURRENT DERMATOLOGY REPORTS, 2020, 9 (04) : 231 - 243
  • [40] Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist
    Simran Chadha
    Andrew J. Para
    Jennifer Choi
    Current Dermatology Reports, 2020, 9 : 231 - 243
12345